<DOC>
	<DOCNO>NCT01261767</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim clinical trial evaluate safety tolerability anti-IL-20 patient psoriasis determine preliminary efficacy expansion phase trial . This trial consist 3 part : A single dose ( SD ) dose-escalation phase 16 week , multiple dose ( MD ) dose-escalation phase 22 week , MD expansion phase 22 week . Initiation MD expansion phase depend result SD MD dose-escalation phase acceptable safety profile present . Subjects participate expansion phase allow participate previous phase ( SD MD dose-escalation phase ) trial .</brief_summary>
	<brief_title>First Human Dose Study Anti-IL-20 Psoriasis : A Study Safety , Tolerability Early Signals Biologic Clinical Effects</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subjects moderate severe stable chronic plaque psoriasis least 6 month , without psoriatic arthritis Affected body surface area ( BSA ) great equal 15 % Physician 's Global Assessment ( PGA ) score 3 Female subject nonchildbearing potential postmenopausal least 1 year . Male subject must agree use effective method birth control Body Mass Index ( BMI ) less equal 38.0 kg/m2 Concomitant antipsoriatic treatment Infectious disease require systemic antiinfectious treatment within 2 week prior administration trial drug Known history Human Immunodeficiency Virus ( HIV ) Hepatitis B and/or C ( determined test ) Live virus bacteria vaccine within last month drug administration Known active herpes/herpes zoster/cold sore Kidney insufficiency Liver insufficiency Lymphoproliferative disease History sign malignancy within last 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>